E

An unexpected surprise!

In our fifth preview from the AACR annual meeting being held in San Diego next month, we noticed some…

March 12, 2024
E

10 things I learned about ADCs at AACR 2024

The good, the bad, and the ugly under belly of the next flurry of ADCs

March 8, 2024
E

What happens when an intractable target becomes druggable-ish

W2W4 - what to watch for in an emerging oncology niche

March 5, 2024
E

Dark side of the moon

What happens when multiple oncogenic pathways converge at the crossroads? An important aspect to watch out for heading into AACR24

February 22, 2024
E

The perils of misreading oncogenic signalling

Finding the right cell/right compartment isn't easy - it requires persistence and dedication

February 13, 2024
E

Exploring novel targets and modalities in advanced cancer

Where we look at half a dozen emerging agents and put them through their paces

February 6, 2024
E

Kicking ADCs up a notch

A twist in the ADC moiety to think about

January 26, 2024
E

Shining a beacon

Our take on data from half a dozen key trials at ASCO GI24

January 24, 2024
E

Thinking outside the box

It's time to look to the future beyond plain vanilla ADCs

January 17, 2024
E

Insights on an emerging competitor landscape

What's next beyond BTK inhibition in lymphomas and CLL?

November 21, 2023
E

Wielding AI’s power for scientific good

Pulling disparate sources together to develop a more optimised approach to targeting oncoproteins

November 16, 2023
E

Pointing the IO way

Eight key areas to watch out for at SITC 2023!

October 27, 2023
E

The Fall and Rise of Essa Pharma

Out of the ashes, a new phoenix can rise

October 23, 2023
E

What to watch out for at TARGETS23 – Part 2

What to watch out for in DDR, epigenetic therapies, and other hot topics

October 11, 2023
E

Ever Decreasing Circles

From epigenetics to SHP2, a look at various upcoming presentations this month

October 5, 2023
E

Gunning for new targets, new approaches

From CAR-T cells to protein degradation

September 19, 2023
E

Adding up the evidence

Early-stage agents in development for multiple myeloma - hit or miss?

September 7, 2023
E

New Developments in Targeting Pancreatic Cancer

Important new preclinical data sets the scene for PDAC

August 30, 2023
E

The scudding clouds of freedom

Finding the sweetspot in early stage cancer drug development

August 16, 2023
E

Important and novel research to be inspired by

Highlighting some outstanding research to take note of

July 25, 2023
E

An under-rated gem at ASCO23

Tackling intractable cancers with a novel and creative approach to the problem

June 8, 2023
E

The weird, the wild, and the wonderful

A discussion of some of the key topics emerging in ER+ HER2- breast cancer

May 15, 2023
E

Heading to the stars in RAS driven cancers

A next generation category of KRAS inhibitors are emerging - W2W4

May 10, 2023
E

AACR23 Insights on gems from the poster halls – Part 1

Where we explain what to look for in 10 posters presented at AACR23

April 25, 2023
E
The key to success in TPD

AACR23 Preview 8 – Keys to success in TPD

W2W4 on the TPD front

April 14, 2023
E

AACR23 Preview 7 – Surfeit of riches

From one compound to many competitors following in their wake!

April 4, 2023
E

AACR23 Preview 6 – Taking a closer look at KRAS Part 1

The ever evolving selective KRAS inhibitor & degrader space

March 29, 2023
E

AACR23 Preview 4 – Stepping It Up

Continuing our evaluation and exploration of another batch of early stage anti-cancer compounds either…

March 20, 2023
E

AACR23 Preview 1 – What to watch for

Half a dozen key early areas to watch out for

March 13, 2023
E

Will targeting KRAS G12D prove more successful than G12C?

Going beyond the first past the post syndrome...

January 25, 2023
E

Kaizen in action

The evolving BMS-Celgene pipeline and what's coming next in new developmental twists

January 10, 2023
E

Moving targets

Ten emerging development areas to watch out for in oncology during 2023

January 5, 2023
E

The evolution of blind spots in hematologic malignancies

A look at an evolving niche in hematologic malignancies

December 16, 2022
E

Exciting new developments in the KRAS space

What started out as a short update from the recent EORTC-NCI-AACR (ENA / Triple Meeting) in Barcelona on…

November 2, 2022
E

On overcoming resistance to protein degraders

Are there opportunities for combining small molecule inhibitors with protein degraders?

October 19, 2022
E

Going beyond PARP1/2 inhibition with novel approaches

Can we overcome resistance checkpoint blockade with novel approaches to DDR?

October 7, 2022
E

Dawn of new directions for protein and glue degraders

Where is the TPD field likely headed with next generation approaches?

October 4, 2022
E

Important new oncology developments to watch out for

6 important and encouraging new developments to watch out for

July 29, 2022
E

A high level view of the latest Target Protein Degradation data

What's the skinny on C4 Therapeutics and other TPD programs at AACR and ASCO?

May 16, 2022
E

Winner, winner, chicken dinner!

5 key and novel early areas of development which stood out to us at AACR22

April 11, 2022
E

An explosion of new opportunities in the expanding KRAS landscape

Going beyond both G12C and G12D to a plethora of new targets and combination approaches

April 10, 2022
E

New directions and opportunities with intractable oncology targets

Just because a pathway has been called undruggable doesn't always mean it will be so!

March 15, 2022
E

AACR22 Preview 1 – Key topics to watch out for

Hot topics to follow at AACR22

March 7, 2022
E

Through the keyhole look at an emerging area of drug development

Some important new research which may stimulate a whole new class of anti-cancer therapies

February 28, 2022
E

To degrade or inhibit, that’s the question

The battle over AR antagonists and degraders rages on as new clinical data emerge

February 23, 2022
E

Going after intractable cancer targets

It's time for an update on novel protein degraders

January 11, 2022
E

Can C4 take protein degraders to new heights?

The intriguing science behind a novel protein degrader platform

January 10, 2022
E

Oncology trends and directions to watch out for in 2022

What to watch out for in 2022

January 7, 2022
E

Novel strategies for addressing an intractable cancer target

A look at some cool science and novel strategies for tackling an intractable target

September 2, 2021
E

Sticking it to MYC addicted cancers and other targets

It's time to tackle some intractable targets in oncology and elsewhere...

August 12, 2021
E

New developments in the protein degradation niche

Update on C4, Kymera, Novartis and Vividion

June 30, 2021
E

When PARP and immunotherapy worlds collide

New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.

May 12, 2021
E

The battle of protein degraders versus inhibitors continues apace

Who's going to win in the battle between protein degraders and small molecule inhibitors?

May 4, 2021
E

Can a monoDAC hit the groove against IMiDs and CELMoDs?

What can we learn from C4 Therapeutics monoDAC, CFT7455?

April 28, 2021
E

A twist in chemical moeity

A look at the subtleties and nuances under the hood of the Arvinas PROTACs

April 27, 2021
E

Highlights and commentary on key AACR21 data presentations

13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?

April 13, 2021
E

AACR21 Preview 3 Novel and cool approaches emerging in oncology pipelines

Emerging areas in cool new science around targeted therapies

March 18, 2021
E

The King of Kings

Capturing attention in the crowded protein degradation niche

March 11, 2021
E

AACR21 Preview 1 Emerging targets for protein degradation and molecular glues

What to watch out for in the protein degradation niche

March 11, 2021
E

The broad and deep protein degradation landscape

Getting to the centre of things with protein degradation

March 9, 2021
E

Strategic direction and future impacts in multiple myeloma

A rock around the myeloma clock through the eyes of a KOL - what stood out and what did not?

January 14, 2021
E

An exciting pipeline of early stage oncology agents from BMS

A critical look at the early stage BMS oncology pipeline

January 11, 2021
E

Important learnings from targeted therapies from SABCS

What's worth following on the targeted therapy front in breast cancer? A look pipelines and new indications from SABCS

December 17, 2020
E

The magic of making proteins disappear

A look at Kymera's protein degrader pipeline

July 21, 2020
E

Hematology Winners and Losers at ASCO20

Which hematology products in development produced the best data at ASCO 2020? We took a look at the key studies in lymphomas and myelomas to find out.

June 4, 2020
E

What’s new in advanced breast cancer?

There are a few new developments of note to consider from ESMO Breast this weekend plus more to come at ASCO20 on Friday

May 26, 2020
E

Will the next generation SERDs make an impact in ER+ HER2- breast cancer?

An in-depth look at the emerging SERD landscape in ER+ metastatic breast cancer

May 21, 2020
E

Is the Arvinas PROTAC Proof of the Pudding?

What do we learn from the initial data with novel PROTAC technology?

May 13, 2020
E

JPM20 Highlights from Day 1

Highlights and lowlights from Day 1 of JPM20

January 13, 2020
E

10 early phase ASH19 abstracts with a difference

A look at off Broadway abstracts on early new product development and scientific findings of interest

November 26, 2019
E

Can a new class of agents therapeutically target the MYC or RAS oncogenes?

How do we go about therapeutically targeting deep protein-protein interactions that can cause aberrant cancer activity? Here's one novel approach in early development...

September 3, 2019